Pharsight

Pharmacyclics Inc patents expiration

1. Imbruvica patents expiration

IMBRUVICA's oppositions filed in EPO
IMBRUVICA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7514444 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Dec, 2026

(3 years from now)

US9181257 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(3 years from now)

US8735403 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(3 years from now)

US8697711 PHARMACYCLICS INC Inhibitors of bruton'S tyrosine kinase
Dec, 2026

(3 years from now)

US8957079 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(3 years from now)

US8008309 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Nov, 2027

(4 years from now)

US10106548 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9725455 PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10125140 PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9296753 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Oct, 2033

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497277 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(3 years from now)

US8703780 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(3 years from now)

US8476284 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(3 years from now)

US8952015 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(3 years from now)

US8754091 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Dec, 2026

(3 years from now)

US8563563 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Apr, 2027

(3 years from now)

US8957079

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8952015

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US9181257

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8754091

(Pediatric)

PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8697711

(Pediatric)

PHARMACYCLICS INC Inhibitors of bruton'S tyrosine kinase
Jun, 2027

(3 years from now)

US8735403

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8476284

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8703780

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8497277

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US7514444

(Pediatric)

PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8563563

(Pediatric)

PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Oct, 2027

(4 years from now)

US8008309

(Pediatric)

PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
May, 2028

(4 years from now)

US10016435 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US8754090 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9801883 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US10478439 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US10653696 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(7 years from now)

US10751342 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9125889 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9801881 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(7 years from now)

US8999999 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US10004746 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9814721 PHARMACYCLICS INC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Jun, 2031

(7 years from now)

US8754090

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US10004746

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US9801883

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US10478439

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US9801881

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(8 years from now)

US10653696

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(8 years from now)

US9814721

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Dec, 2031

(8 years from now)

US10016435

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US9125889

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US10751342

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US8999999

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US9713617 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10752634 PHARMACYCLICS INC Crystalline forms of a brutons tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10961251 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10294232 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10294231 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9540382 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Aug, 2033

(9 years from now)

US10125140

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(10 years from now)

US10752634

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a brutons tyrosine kinase inhibitor
Dec, 2033

(10 years from now)

US10961251

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(10 years from now)

US9725455

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(10 years from now)

US9713617

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(10 years from now)

US10106548

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(10 years from now)

US10294231

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(10 years from now)

US10294232

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(10 years from now)

US9540382

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Feb, 2034

(10 years from now)

US9296753

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Apr, 2034

(10 years from now)

US9795604 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Oct, 2034

(11 years from now)

US10695350 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Oct, 2034

(11 years from now)

US10463668 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Oct, 2034

(11 years from now)

US9795604

(Pediatric)

PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Apr, 2035

(11 years from now)

US10695350

(Pediatric)

PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Apr, 2035

(11 years from now)

US10463668

(Pediatric)

PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Apr, 2035

(11 years from now)

US10213386 PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(12 years from now)

US10010507 PHARMACYCLICS INC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Mar, 2036

(12 years from now)

US10828259 PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(12 years from now)

US9655857 PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(12 years from now)

US10828259

(Pediatric)

PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US9655857

(Pediatric)

PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US10213386

(Pediatric)

PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US10010507

(Pediatric)

PHARMACYCLICS INC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2029
New Product (NP) Aug 24, 2025
Pediatric Exclusivity (PED) Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 24 August, 2022

Treatment: Treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of waldenstrom's macroglobulinemia; Treatment of mantle cell lymphoma; Treatment of small lymphocytic lymphoma; Treatment of chro...

Dosage: SUSPENSION;ORAL

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic